Cointime

Gentis

company

About

Gentis develops biomaterials-based products for the treatment of early-stage degeneration of the spine.

  • 11 - 50

Highlights

Total Funding Amount
$10.54M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Series A
Last Funding Money Raised
$10M
Industries
Biotechnology,Health Care,Manufacturing,Medical,Medical Device,Wellness
Founded date
Jan 1, 2000
Number Of Employee
11 - 50
Operating Status
Active

Gentis is a developer of minimally invasive, biomaterials-based products intended to treat the early-stage degeneration of the spine. The company's patented product is DiscCell, an injectable, in-situ setting, radio-opaque, non-hydrogel polymer material that augments or replaces the diseased nucleus pulposus of the spinal disc.

Gentis was founded on 2000 and is headquartered in Wayne, Pennsylvania.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$10.54M
Gentis has raised a total of $10.54M in funding over 2 rounds. Their latest funding was raised on Jul 19, 2010 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 19, 2010 Series Unknown $548.26K 1 — — Detail
Jun 21, 2007 Series A $10M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
Gentis is funded by 2 investors. Matignon Technologies and Matignon Investissement & Gestion are the most recent investors.
Investor Name Lead Investor Funding Round
Matignon Technologies — Series Unknown
Matignon Investissement & Gestion — Series A
Cointime
เนื้อหา
บริษัท